candy/cez, talking to yourself again? You have "been on to something" with all your predictions which have all been wrong. Even the blind squirrel finds the nut once in a while so who knows, eventually you might be right once just by dumb luck. And no one is dumber than you.
Candy, is this like your prediction when the stock was $6 that it was going to $3 when instead it went to $11? Your track record is rather dismal on MDXG, dismal meaning you are batting 0%.
Coverage Reit/Price Tgt Changed*
$39 » $7
UBS note today with a buy rec and lowered price target from $29 to $7. This of course is an adjustment from what their target was pre spin off..looks comparable or maybe a tad higher. In any event, that is what drove the stock today.
January 28, 2015
Post-RARP Potency, Continence Return Faster with Amniotic Nerve Wrap
Placing a dehydrated human amniotic membrane allograft nerve wrap around the prostatic neurovascular bundle appears to encourage early return to continence and potency following nerve-sparing robot-assisted radical prostatectomy (RARP), a new study finds.
Despite the advantages of RARP, even patients with well-preserved neurovascular bundles (NVBs) have a convalescent period characterized by incontinence and impotence, researchers noted. “This delay is probably due to an inflammatory response caused by traction injury to the NVB,” they stated.
Amniotic nerve wraps have been used for wound healing in other types of surgery. The amniotic membrane contains factors that may promote nerve cell survival and axon regeneration after RARP, they suggest.
For the study, Vipul R. Patel, MD, and colleagues at Florida Hospital-Celebration Health in Celebration, Florida, studied 58 patients who underwent full nerve-sparing RARP at the institution from March 2013 to July 2014 and received the graft. A single surgeon performed all of the procedures. The amniotic membrane was cut into two long pieces and placed over each neurovascular bundle as a nerve wrap after removal of diseased tissue and anastomosis.
For comparison, the investigators used a computer system to find a similar set of 58 RARP patients who received no graft. All patients were continent and potent before surgery. Following surgery, some patients took phosphodiesterase type 5 inhibitors.
At 8 weeks after surgery, 81% of patients who had received the graft were continent (versus 74.1% of the no-graft group), according to results published online ahead of print in European Urology. In addition, 65.5% of graft patients had returned to potency (compared with 51.7% of the no-graft group). The average time to potency and continence were significantly shorter in the graft group: 1.34 versus 3.39 months and1.21 versus 1.83 months
By the way, this report is available on their website. The report is dated October 1, 2014 when they initiated with a $21 target. Reports liek this with targets liek that lack credibility and no more than pump and dump material. Look, I own PSTI but ths target is silly
Candy, talking about yourself in the third person is a tell tale sign of mental illness.
Widener Law School? Seriously? I looked to see where it was ranked in US News & World Report, the best source for college rankings, and its unranked. A boutique law firm? Usually boutique is used by firms stocked with Ivy grads, Northwestern, U of Chicago, etc.
Funny. What they woudl tell you is that they are looking for people who bought in the $11s and then the stock dropped to the $8s after they bought, claiming that they would not have bought had they known that "management did something wrong". of course, when yiu can't prove they did, there is no case. Insurance compaies often selttle for nuisance value though. Ambulance chasers get paid and no one else. Insurance substantailly covers these types of claims anyway so they are not material to the companies.
silverfox. I read the document yesterday morning. Yes, that would be a better explanation. Initial studies have shown that EpiFix and Amniofx improve the recovery of heart tissue after an event, i.e. regenerate. This has the potential to be a gamechanger for the company and significantly increase its value as a target in my opinion.
I was just reading the actual note. I agree with his point 1 regarding OSIR. However, he is wrong regarding point 4. It's not having any impact and will not.
tny, almost zero chance he will retire. In my opinion, 75% chance of a sale in 2015, 24 % chance in 2016.
tny501, easy answer. Because, Petit is not in his infancy, he is 75 years old and there was never a long term plan beyond building it and selling. He's not going to wait until he is 80
From Brean Capital's recent initiation note. Since they talk to management they have a window into management's expectations
We used DCF and EV/Sales metrics to determine our target price. Industry median EV/sales for companies in the comp group is 6.3x. When we apply this multiple to OSIR’s estimated 2015 sales of $93 million, we arrive at a value of $19. Our DCF methodology yielded a similar value of $19 when using a ten year cash flow discounted at 10%; revenues from the US market only, an approach which we view as conservative; and terminal value of 1x the tenth year cash flow. Our final price target is reached by averaging the two.